N/A
Completed N=1,389
PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
Rheumatic Diseases · Arthralgia · Myalgias/Myopathy · lumbago
Source: ClinicalTrials.gov NCT00922428 ↗
Enrolled (actual)
1,389
Serious AEs
0.0%
Results posted
May 2015
Primary outcomePrimary: Visual Analog Scale (VAS) — 6.57; 4.23; 2.61 units on a scale
Summary
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Scale (VAS) |
6.57; 4.23; 2.61 | — |
| PRIMARY Tolerability of the Drug |
2.8; 97.2 | — |
| PRIMARY Pain at Rest |
57.5; 76.8; 44.1 | — |
| PRIMARY Pain in Movement |
67.5; 80.8; 50.1 | — |
| PRIMARY Pain After Rest |
60.2; 78.6; 49.8 | — |
| PRIMARY Pain on Weight-bearing |
64.1; 79.1; 50.4 | — |
| PRIMARY Morning Stiffness |
54.4; 74.5; 42.9 | — |
| PRIMARY Tenderness |
64.5; 80.8; 50.3 | — |
| PRIMARY Antalgic Position |
61.3; 79.4; 43.4 | — |
| SECONDARY Acceptance of the Drug |
90.5; 8.7 | — |
Eligibility Criteria
Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group".
Observational Criteria (=inclusion criteria for documentation):
- Males and females
- At least 18 years old
- Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
Exclusion criteria for documentation:
- younger than 18 years
- no Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
- no treatment with PASCOE-Agil HOM-Injektopas
Data sourced from ClinicalTrials.gov (NCT00922428). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.